Chart Events
Performance Outlook
| Previous Close | 154.70 |
| Open | 155.66 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 154.53 - 155.86 |
| 52 Week Range | 95.02 - 155.86 |
| Volume | |
| Avg. Volume | 1,441,591 |
| Market Cap | 348.992B |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | 53.16 |
| EPS (TTM) | 2.92 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.77 (1.27%) |
| Ex-Dividend Date | Mar 24, 2023 |
| 1y Target Est | 140.39 |
- Zacks
Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal
Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 27 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme i
- Zacks
Here's How Much You'd Have If You Invested $1000 in Novo Nordisk a Decade Ago
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
